RESEARCH-USE BIOSIMILAR ANTIBODY
Manelimab
Monoclonal antibody · IgG1
Manelimab (BCD-135) is a monoclonal antibody targeting PD-L1 with PD-L1 inhibitory activity. Manelimab blocks the interaction between PD-L1 and PD-1 to abrogate the immunosuppressive signals of T cells in the tumor microenvironment. Manelimab is applicable for tumor-related research.
TARGETPDL1
YMonoclonal antibody
CATALOGSC-BS-387
CATALOG NUMBERSC-BS-387
MOLECULAR WEIGHTLot-specific
PRODUCT FORMATMonoclonal antibody
PRODUCT OVERVIEW
A research-use configuration for comparative antibody studies
Manelimab (BCD-135) is a monoclonal antibody targeting PD-L1 with PD-L1 inhibitory activity. Manelimab blocks the interaction between PD-L1 and PD-1 to abrogate the immunosuppressive signals of T cells in the tumor microenvironment. Manelimab is applicable for tumor-related research.
Manelimab is a recombinant research-use antibody directed against PDL1.